North America Tumor Ablation Market Research Report – Segmented By Technology, Treatment, Application & Country (The U.S., Canada and Rest of North America) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2024 to 2029)

Updated On: January, 2024
ID: 428
Pages: 135

North America Tumor Ablation Market Size (2023 to 2028)

The size of the North American tumor ablation market is estimated to grow at a CAGR of 11.2% from 2023 to 2028.

Tumors are the group of abnormal cells that accumulate together and form lumps. Tumor ablation is a minimally invasive procedure that destroys cancer cells in the chest, lung, and liver.

The rising prevalence of cancer is proportional to the growth of the tumor ablation market. As per data published by the American Cancer Society, cancer incidence in the United States is 300.2 per 100,000 annually. Similarly, in Canada, the number is somewhere around 236.6 cases.

North America Tumor ablation market is driven by critical factors such as the growing geriatric population, the increasing number of people affected with cancer, and technological advancements in ablation. In addition, increasing demand for minimally invasive cancer treatment procedures and favorable reimbursement structures coupled with rising disposable income are other major factors fuelling the market's growth.

However, ablation procedures and stringent regulatory guidelines delaying product launches are restraining the market growth.

This research report on the North American tumor ablation market has been segmented and sub-segmented into the following categories:

By Technology: 

  • Radiofrequency Ablation Devices
  • Microwave Ablation Devices
  • Cryoablation Devices
  • Other Ablation Devices

By Treatment: 

  • Surgical Ablation
  • Laparoscopic Ablation
  • Percutaneous Ablation

By Application: 

  • Liver Cancer
  • Breast Cancer
  • Lung Cancer
  • Prostrate Metastasis
  • Other Cancer

By Country: 

  • The U.S.
  • Canada
  • Rest of North America

Regionally, North America is the largest market for tumor ablation globally, with over 33% share owing to its advanced healthcare infrastructure, Y-O-Y growth in the incidence of various types of cancers, growing inclinations of the patients towards cancer treatment, and rising government funds for cancer research. Within North America, the U.S. tumor ablation market is predicted to occupy most of the share due to favorable reimbursement policies, high government support, and a high success rate of tumor ablation. The tumor ablation procedure has been used to treat liver cancer, prostate cancer, and more.

At the same time, the Canadian tumor ablation market is estimated to register a healthy CAGR during the forecast period due to the increasing incidence. Rising research and development funds, concentration on the development of the products with new features supports the market growth in Canada. The rising burden of cancer, the growing cancer occurrence rate, is 296.6 cases per 100,000 people every year. Every one in six deaths has been occurred because of cancer globally.


A few notable players operating in the North American Tumor Ablation Market profiled in this report are Medtronic Plc., Boston Scientific Corporation, Angiodynamics, Mermaid Medical, HealthTronics, Galil Medical Inc., EDAP TMS S.A., SonaCare Medical, Misonix, Inc. and Neuwave Medical, Inc.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1400

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample